AMULET IDE: New Research Compares WatchMan and Amulet Devices Providing New Evidence

Recently, at the TCT Congress results from the SWISS-APERO study comparing Watchman and Amulet devices were presented. Now, a new study, Amulet IDE—published in Circulation—, compared both devices on a large number of patients.

AMULET Die: Un nuevo estudio compara los dispositivos Watchman y Amulet y arroja nueva evidencia

Amulet IDE was designed to evaluate the safety and efficacy of dual-seal mechanism device Amulet compared with the Watchman (a widely used tool in clinical practice).

In this sense, the Amulet device was non-inferior in terms of safety and efficacy to prevent stroke in patients with nonvalvular atrial fibrillation compared with the Watchman device. Atrial appendage occlusion was superior with Amulet—a result also observed in SWISS-APERO.

In this study, 1878 patients with nonvalvular atrial fibrillation and at high risk of stroke were randomized to receive either device. The primary safety endpoint was a composite of procedure-related complications, all-cause mortality, or major bleeding.

The efficacy endpoint was a composite of ischemic stroke or systemic embolism at 18 months. Atrial appendage seal at 45 days was also considered.

In terms of safety, Amulet proved to be non-inferior to Watchman (14.5% vs. 14.7%; p < 0.001).


Read also: TCT 2021 | SWISS-APERO: Difference in Leaks between the Amulet and the Watchman.


However, results were similar for major bleeding and death (10.6% vs. 10.0%, and 3.9% vs. 5.1%, respectively).

Procedure-related complications (pericardial effusion and device embolization) were higher with Amulet (4.5% vs. 2.5%).

Conclusion

The Amulet atrial appendage occluder device was non-inferior in terms of safety and efficacy for stroke prevention in patients with nonvalvular atrial fibrillation. Peri-procedural complications were higher with Amulet, but decreased with increased operator experience.

amulet-die

Original Title: Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE).

Reference: Dhanunjaya Lakkireddy et al. Circulation. 2021 Nov 9;144(19):1543-1552. doi: 10.1161/CIRCULATIONAHA.121.057063.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

OPTION Trial: Left Atrial Appendage Closure

Atrial fibrillation ablation is a valid strategy. However, reoccurrence is frequent in these cases, often with asymptomatic presentation. Anticoagulation with warfarin has proven effective in...

TRI-SPA Study: Tricuspid Edge-to-Edge Treatment

Tricuspid regurgitation (TR) is a condition associated with high morbidity and mortality. Currently, surgery is the recommended treatment; however, it carries a high complication...

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...